OtherClinical Investigations (Human)
HIGHLY INCREASED 125I-JR11 ANTAGONIST BINDING IN VITRO REVEALS NOVEL INDICATIONS FOR SST2 TARGETING IN HUMAN CANCERS
Jean Claude Reubi, Beatrice Waser, Helmut R. Maecke and Jean E. Rivier
Journal of Nuclear Medicine August 2016, jnumed.116.177733; DOI: https://doi.org/10.2967/jnumed.116.177733
Jean Claude Reubi
1 University of Bern, Switzerland;
Beatrice Waser
2 Univ. of Bern, Inst. of Pathology, Switzerland;
Helmut R. Maecke
3 Universitätsklinikum Freiburg, Germany;
Jean E. Rivier
4 The Salk Institute for Biological Studies, United States
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
HIGHLY INCREASED 125I-JR11 ANTAGONIST BINDING IN VITRO REVEALS NOVEL INDICATIONS FOR SST2 TARGETING IN HUMAN CANCERS
Jean Claude Reubi, Beatrice Waser, Helmut R. Maecke, Jean E. Rivier
Journal of Nuclear Medicine Aug 2016, jnumed.116.177733; DOI: 10.2967/jnumed.116.177733
Jump to section
Related Articles
Cited By...
- Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
- P2X7 PET Radioligand 18F-PTTP for Differentiation of Lung Tumor from Inflammation
- New Developments in Peptide Receptor Radionuclide Therapy
- Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists
- Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists
- Somatostatin Antagonists for Radioligand Therapy of Nonendocrine Tumors
- Molecular Imaging of Human Embryonic Stem Cells Stably Expressing Human PET Reporter Genes After Zinc Finger Nuclease-Mediated Genome Editing
- SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- Somatostatin Receptor Antagonists for Imaging and Therapy
- Approaches to Multireceptor Targeting: Hybrid Radioligands, Radioligand Cocktails, and Sequential Radioligand Applications
- Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
- Citius, Altius, Fortius: An Olympian Dream for Theranostics